ArticleFrontiers in nutrition2023
Association between daidzein intake and metabolic associated fatty liver disease: A cross-sectional study from NHANES 2017-2018.
Article in Frontiers in nutrition, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- The gut microbiome mediates the association between a flavonoid-rich diet and MASLD in a population-level analysis.European journal of nutrition · 2025Article
- Gut microbiome composition and metabolic activity in metabolic-associated fatty liver disease.Virulence · 2025Article
- Role of isoflavones in multiple sclerosis.IBRO neuroscience reports · 2025Review
- Pharmacotherapeutic potential of daidzein: insights into mechanisms and clinical relevance.Inflammopharmacology · 2025Review
- Dietary Inflammatory index and its association with fatty liver disease: a study in obese and non-obese populations.BMC gastroenterology · 2025Article
- MethylEnvironment & health (Washington, D.C.) · 2025Article
- Development of a diagnostic model for MASLD and identification of daidzein as the potential drug using bioinformatics analysis and experiments.Frontiers in immunology · 2025Article
- Mechanism of Lipi Jiangzhuo Decoction in Improving Metabolic Dysfunction-Associated Steatohepatitis Through the PERK/PINK1/GPx4 Pathway.Journal of inflammation research · 2025Article
- Association between the composite dietary antioxidant index and metabolic dysfunction-associated steatotic liver disease in adults: a cross-sectional study from NHANES 2017-2020.Scientific reports · 2024Article
- A comprehensive investigation on the chemical changes of traditional Chinese medicine with classic processing technology: Polygonum multiflorum under nine cycles of steaming and sunning as a case study.Analytical and bioanalytical chemistry · 2024Article
- Multivitamin consumption and childhood asthma: a cross-sectional study of the NHANES database.BMC pediatrics · 2024Article
- Exploring the impact of polychlorinated biphenyls on comorbidity and potential mitigation strategies.Frontiers in public health · 2024Article
- Association between composite dietary antioxidant index and fatty liver index among US adults.Frontiers in nutrition · 2024Article
- Sex Hormone: A Potential Target at Treating Female Metabolic Dysfunction-Associated Steatotic Liver Disease?Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic associated fatty liver disease (MAFLD) has become the most common liver disease globally, yet no new drugs have been approved for clinical treatment. Therefore, we investigated the relationship between dietary intake of soy-derived daidzein and MAFLD, to find potentially effective treatments. Methods: We conducted a cross-sectional study using data from 1,476 participants in National Health and Nutrition Examination Survey (NHANES) from 2017 to 2018 and their associated daidzein intake from the flavonoid database in the USDA Food and Nutrient Database for Dietary Studies (FNDDS). We investigated the relationship between MAFLD status, controlled attenuation parameter (CAP), AST/Platelet Ratio Index (APRI), Fibrosis-4 Index (FIB-4), liver stiffness measurement (LSM), nonalcoholic fatty liver disease (NAFLD) fibrosis score (NFS), hepatic steatosis index (HSI), fatty liver index (FLI), and daidzein intake by adjusting for confounding variables using binary logistic regression models and linear regression models. Results: In the multivariable-adjusted model II, there was a negative association between daidzein intake and the incidence of MAFLD (OR for Q4 versus Q1 was 0.65, 95% confidence interval [CI] = 0.46-0.91, Conclusion: We found that MAFLD prevalence, CAP, HSI, and FLI, all decreased with increased daidzein intake, suggesting that daidzein intake may improve hepatic steatosis. Therefore, dietary patterns of soy food or supplement consumption may be a valuable strategy to reduce the disease burden and the prevalence of MAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.